Rohitukine

Synonyms: 罗希吐碱
Rohitukine 是一种具有口服活性的 CDK9/T1 抑制剂(IC50 为 0.3 μM),可阻断 Cdk2/A 和 Cdk9/T1 的 ATP 结合位点,抑制 PPARγ、AKT、mTOR、C/EBPα、SREBP-2 和 NF-κB 信号通路,并上调肝脏 LXRα 的表达,同时可诱导细胞周期 S 期阻滞、ROS 生成和细胞凋亡 (apoptosis),且具有抗炎活性,可用于白血病、胰腺癌、前列腺癌、乳腺癌、中枢神经系统癌症、卵巢癌、肺癌、血脂异常、炎症性疾病、炎症性肠病及关节炎的研究。
产品编号: MS-H38290 CAS No.: 71294-60-5 分子式: C16H19NO5 分子量: 305.33
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Rohitukine 是一种具有口服活性的 CDK9/T1 抑制剂(IC50 为 0.3 μM),可阻断 Cdk2/A 和 Cdk9/T1 的 ATP 结合位点,抑制 PPARγ、AKT、mTOR、C/EBPα、SREBP-2 和 NF-κB 信号通路,并上调肝脏 LXRα 的表达,同时可诱导细胞周期 S 期阻滞、ROS 生成和细胞凋亡 (apoptosis),且具有抗炎活性,可用于白血病、胰腺癌、前列腺癌、乳腺癌、中枢神经系统癌症、卵巢癌、肺癌、血脂异常、炎症性疾病、炎症性肠病及关节炎的研究。

生物实验数据

生物活性 Rohitukine is an orally active CDK9/T1 inhibitor with an IC50 of 0.3 μM that blocks the ATP-binding sites of Cdk2/A and Cdk9/T1, inhibits the PPARγ, AKT, mTOR, C/EBPα, SREBP-2, and NF-κB signaling pathways, and upregulates hepatic LXRα expression, while also inducing S-phase cell cycle arrest, ROS generation, and apoptosis (apoptosis), and exhibiting anti-inflammatory activity, making it applicable to research on leukemia, pancreatic cancer, prostate cancer, breast cancer, central nervous system cancers, ovarian cancer, lung cancer, dyslipidemia, inflammatory diseases, inflammatory bowel disease, and arthritis.
IC50 & Target

CDK2/A

7.5 μM (IC50)

CDK9/T1

0.3 μM (IC50)

体外研究
(In Vitro)

Rohitukine (48 h) 表现出选择性的体外癌细胞细胞毒性,对 HL-60 白血病细胞的活性最强 (GI50 = 10 μM),对 Molt-4 白血病细胞的活性次之 (GI50 = 12 μM),而对正常 fR2 和 HEK-293 细胞系的细胞毒性极低 (GI50 > 50 μM)。
Rohitukine (1-10 μM) 可在体外以浓度依赖的方式诱导 HL-60 白血病细胞发生 S 期细胞周期阻滞。
Rohitukine 可在无细胞生化实验中强效抑制 Cdk9/cyclin T1 (IC50 = 0.3 μM),并弱效抑制 Cdk2/A (IC50 = 7.3 μM)。
Rohitukine (50 μM) 在无细胞谱分析实验中可强效抑制 Dyrk1A、AMPK 和 VEGFR 激酶。
Rohitukine (5-20 μM; 2-8 days) 可呈浓度和时间依赖性抑制 3T3-L1 和 C3H10T1/2 脂肪细胞中的脂质积累。
Rohitukine (20 μM; 6 days) 可下调 3T3-L1 脂肪细胞中促脂肪生成基因 (LPL、aP2、SREBP-1c、FAS、PPARγ) 的表达,并上调抗脂肪生成基因 (Wnt3a、GATA2) 的表达。
Rohitukine (20 μM; 15 min-6 days) 可下调晚期成脂蛋白的表达 (PPARγ、C/EBPα、aP2、FAS、GLUT4),抑制 3T3-L1 脂肪细胞中的早期 AKT/mTOR/4EBP 信号通路。
Rohitukine (1-20 μM; 24 h) 可呈浓度依赖性地将 3T3-L1 前脂肪细胞阻滞于有丝分裂克隆扩增过程的 S 期。
Rohitukine (20 μM; 16-24 h) 可下调 3T3-L1 前脂肪细胞中细胞周期进程相关蛋白 (cyclin-D、CDK6、CDK4、cyclin-E、CDK2、C/EBPβ) 的表达,并稳定 CDK 抑制剂 P27。
Rohitukine (20 μM; 48 h) 可显著抑制有丝分裂克隆扩增阶段 3T3-L1 前脂肪细胞的增殖。
Rohitukine (3-100 μM; 24 h) 对 J774A.1 巨噬细胞无细胞毒性,其细胞毒性 IC50 >50 μM。
Rohitukine (3-30 μM; 1 h pretreatment, followed by 18 h incubation) 可剂量依赖性地抑制 LPS (MS-X54539) 诱导的 J774A.1 巨噬细胞中一氧化氮的产生。
Rohitukine (3-30 μM; 18 h) 抑制 LPS 诱导的 J774A.1 巨噬细胞中活性氧的生成。
Rohitukine (3-30 μM; 1 h pretreatment, followed by 18 h incubation) 可抑制 LPS 诱导的 J774A.1 巨噬细胞中 IL-1β、TNF-α、IL-6 和 PGE2 的产生。
Rohitukine (3-30 μM; 1 h pretreatment, followed by 18 h incubation) 可剂量依赖性地抑制 LPS 诱导的 J774A.1 巨噬细胞中 NF-κB 的转录活性。
Rohitukine (10-30 μM; 1 h pretreatment, followed by incubation) 可在 10 μM 和 30 μM 浓度下抑制 LPS 诱导的 J774A.1 巨噬细胞中 NF-κB 的核转位。
Rohitukine (10-30 μM; 1 h pretreatment, followed by 2 h incubation) 可抑制 LPS 诱导的 J774A.1 巨噬细胞中 iNOS 和 COX-2 蛋白表达。
Rohitukine (10-30 μM; 1 h pretreatment, followed by 30 min incubation) 可通过降低 IκB-α 磷酸化水平并维持胞质 NF-κB p65 的含量,抑制 LPS 诱导的 NF-κB 通路激活;还可通过降低 ERK 和 JNK 的磷酸化水平,抑制 LPS 诱导的 MAPK 通路激活。
Rohitukine (3-30 μM; 48 h) 对原代小鼠腹腔巨噬细胞的毒性极低,在浓度高达 50 μM 时仍无毒性,并可剂量依赖性地抑制 LPS 诱导的 NO 生成以及 IL-1β、IL-6 和 TNF-α 的释放。
Rohitukine (0.25-1.0 mM) 可剂量依赖性地抑制 5 周龄野生型拟南芥 (Col-0) 植株的生长。
Rohitukine (0.25-1.0 mM) 可呈剂量依赖性诱导 5 周龄野生型拟南芥 (Col-0) 植株中 ROS 的积累,并提高其抗氧化酶活性。

Cell Differentiation Assay

Cell Line: 3T3-L1, C3H10T1/2 adipocytes
Concentration: 5; 10; 15; 20 μM
Incubation Time: 2; 4; 6; 8 days
Result: Inhibited lipid accumulation in a concentration-dependent manner.
Significantly reduced lipid accumulation at 5 μM.
Inhibited >80% of MDI-induced lipid accumulation at 20 μM in both cell lines.
Reduced lipid accumulation across all time windows of 20 μM exposure, with maximum inhibition seen with 0-6 days exposure.
Caused a significant reduction in lipid accumulation in 3T3-L1 cells with the shortest 0-2 days exposure.

Real Time qPCR

Cell Line: 3T3-L1 adipocytes
Concentration: 20 μM
Incubation Time: 6 days (gene expression); 48 h (Wnt3a/GATA2 expression)
Result: Significantly reduced mRNA expression of pro-adipogenic genes LPL, aP2, SREBP-1c, FAS, and PPARγ.
Caused a nonsignificant decreasing trend in C/EBPα mRNA expression.
Increased mRNA expression of anti-adipogenic transcription factors Wnt3a and GATA2 significantly after 48 h of exposure.

Western Blot Analysis

Cell Line: 3T3-L1 adipocytes
Concentration: 20 μM
Incubation Time: 15; 30; 60; 120 min; 2; 4; 6; days
Result: Significantly suppressed late-phase protein expression of PPARγ, C/EBPα, aP2, FAS, and GLUT4 on days 2, 4, and 6 of differentiation.
Significantly reduced phosphorylation of AKT (Ser473), mTOR (Ser2448), and 4EBP (Thr37/46) within 2 hours of induction.

Cell Cycle Analysis

Cell Line: 3T3-L1 preadipocytes
Concentration: 1; 3; 10; 20 μM
Incubation Time: 24 hours
Result: Caused a concentration-dependent increase in the percentage of cells in S phase.
Induced S-phase arrest during mitotic clonal expansion, with 41.15% of cells in S phase at 20 μM, compared to 19.28% in MDI-only treated cells.

Western Blot Analysis

Cell Line: 3T3-L1 preadipocytes
Concentration: 20 μM
Incubation Time: 16; 24 h
Result: Reduced protein expression of cyclin-D, CDK6, CDK4, cyclin-E, CDK2, and C/EBPβ at 16 and 24 hours post-induction.
Stabilized expression of the CDK inhibitor P27.

Cell Viability Assay

Cell Line: J774A.1 macrophage cells
Concentration: 3; 10; 30; 100 μM
Incubation Time: 24 h
Result: Showed no cytotoxic effects across all tested concentrations, with cell viability remaining near control levels both with and without LPS co-treatment.
Determined a cytotoxic IC50 >50 μM.

ELISA Assay

Cell Line: J774A.1 macrophage cells
Concentration: 3; 10; 30 μM
Incubation Time: 1 h pretreatment, followed by 18 h incubation
Result: Inhibited LPS-induced release of IL-1β (46%), TNF-α (29%), IL-6 (31%), and PGE2 (48%) at 30 μM compared to the LPS-only control.
Showed inhibitory effects at lower concentrations in a dose-dependent manner.

Immunofluorescence

Cell Line: J774A.1 macrophage cells
Concentration: 10; 30 μM
Incubation Time: 1 h pretreatment
Result: Significantly reduced LPS-induced nuclear translocation of NF-κB, as measured by decreased fluorescent intensity of nuclear NF-κB.
Showed statistically significant inhibition at both 10 μM and 30 μM compared to the LPS-only group.

Western Blot Analysis

Cell Line: J774A.1 macrophage cells
Concentration: 10; 30 μM
Incubation Time: 1 h pretreatment, followed by 2 h incubation
Result: Reduced LPS-induced iNOS and COX-2 protein levels by 54% and 68%, respectively, at 30 μM.
Produced significant inhibitory effects on both proteins at 10 μM.

Western Blot Analysis

Cell Line: J774A.1 macrophage cells
Concentration: 10; 30 μM
Incubation Time: 1 h pretreatment, followed by 30 min incubation
Result: Downregulated LPS-induced phosphorylation of IκB-α.
Reduced LPS-induced depletion of cytosolic NF-κB p65.
Inhibited LPS-induced phosphorylation of ERK (27% inhibition at 30 μM) and JNK (54% inhibition at 30 μM).
体内研究
(In Vivo)

Rohitukine (50 mg/kg;口服;每日 1 次;连续 7 天) 可显著改善叙利亚金黄仓鼠由高脂饮食诱导的血脂异常,减少肝脏和性腺的脂质积累,并调控关键的脂类调节基因与蛋白。
Rohitukine (12.5-50 mg/kg;口服;每日一次;连续 5 天) 可剂量依赖性地抑制 LPS 诱导的小鼠促炎细胞因子产生。
Rohitukine (12.5-50 mg/kg;口服;单次给药) 可剂量依赖性地降低小鼠体内醋酸 (MS-H89626) 诱导的血管通透性。
Rohitukine (12.5-50 mg/kg;口服;单剂量) 可剂量依赖性地抑制角叉菜胶 (MS-L60716) 诱导的大鼠足肿胀。
Rohitukine (12.5-50 mg/kg;口服;单次给药) 可抑制角叉菜胶诱导的小鼠胸膜炎。
Rohitukine (12.5-50 mg/kg;口服;每日一次;连续 14 天) 可剂量依赖性地减轻 Wistar 大鼠中弗氏完全佐剂诱导的关节炎。

Animal Model: Syrian golden hamster (8-week-old, 100-120 g body weight, dyslipidemia induced by 45% kcal high-fat diet for 10 days)
Dosage: 50 mg/kg
Administration: p.o.; once daily; 7 days
Result: Reduced body weight gain significantly compared to HFD and pair-fed groups.
Reduced plasma total cholesterol, triglycerides, LDL-cholesterol, and HDL-cholesterol levels significantly relative to the pair-fed group.
Increased HDL-cholesterol/total cholesterol ratio significantly.
Increased hepatic mRNA expression of liver X receptor α 4-fold.
Reduced LDL receptor, HMG-CoA reductase, and sterol-regulatory element binding protein 2 expression significantly.
Decreased epididymal adipose tissue weight significantly compared to HFD-fed animals.
Reduced protein expression of peroxisome proliferator-activated receptor γ, fatty acid synthase, adipocyte protein 2, and glucose transporter 4 in epididymal adipose tissue.
Reduced lipid accumulation in liver, smaller adipocyte size, and reduced pancreatic lipid droplets compared to HFD-fed hamsters.
Animal Model: BALB/c mice (male, 22-25 g, LPS-induced pro-inflammatory cytokine production model)
Dosage: 12.5; 25; 50 mg/kg
Administration: p.o.; daily; 5 days
Result: Inhibited LPS-induced IL-1β production by 58%, TNF-α production by 45%, and IL-6 production by 38% at 50 mg/kg.
Significantly reduced IL-1β and TNF-α levels at 25 mg/kg.
Reduced IL-1β, TNF-α, and IL-6 levels compared to the LPS-only group at 12.5 mg/kg.
Animal Model: BALB/c mice (male, 22-25 g, acetic acid-induced vascular permeability model)
Dosage: 12.5; 25; 50 mg/kg
Administration: p.o.; single dose
Result: Reduced Evans blue leakage by 12.1% at 12.5 mg/kg, 39.3% at 25 mg/kg, and 75.7% at 50 mg/kg compared to the acetic acid control group.
Animal Model: Wistar rats (male, 120-140 g, Carrageenan (MS-L60716)-induced paw oedema model)
Dosage: 12.5; 25; 50 mg/kg
Administration: p.o.; single dose
Result: Suppressed paw oedema by 25% at 12.5 mg/kg, 35% at 25 mg/kg, and 58% at 50 mg/kg compared to the carrageenan control group.
Animal Model: BALB/c mice (male, 22-25 g, carrageenan-induced pleurisy model)
Dosage: 12.5; 25; 50 mg/kg
Administration: p.o.; single dose
Result: Inhibited pleuritic exudate volume by 59.95% and total leukocyte migration by 86.04% at 50 mg/kg.
Inhibited exudate volume by 61.43% and leukocyte migration by 82.43% at 25 mg/kg.
Inhibited exudate volume by 5.90% and leukocyte migration by 36.82% at 12.5 mg/kg.
Animal Model: Wistar rats (male, 120-140 g, Freund's complete adjuvant-induced arthritis model)
Dosage: 12.5; 25; 50 mg/kg
Administration: p.o.; daily; 14 days
Result: Inhibited paw oedema by 54%, reduced TNF-α levels by 52%, IL-6 levels by 68%, and IL-1β levels by 71% compared to the arthritic disease control group at 50 mg/kg.
Restored serum SGPT, creatinine, and triglyceride levels to near normal at 50 mg/kg.
Augmented serum SOD, CAT, and GST levels by 96%, 94%, and 98% respectively compared to the arthritic group at 50 mg/kg.
Improved spontaneous motor activity to 39.90 at 50 mg/kg.
Maintained joint architecture with reduced bone erosion on radiographs at 50 mg/kg.
Prevented body weight loss in all treated groups.

化学信息

分子量 305.33
分子式 C16H19NO5
CAS No. 71294-60-5
别名 罗希吐碱

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

罗希吐碱 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础